



Imm, J., Kerrigan, T. L., Jeffries, A., & Lunnon, K. (2017). Using induced pluripotent stem cells to explore genetic and epigenetic variation associated with Alzheimer's disease. *Epigenomics*, 9(11), 1455-1468. <https://doi.org/10.2217/epi-2017-0076>

Peer reviewed version

License (if available):
Other

Link to published version (if available):
[10.2217/epi-2017-0076](https://doi.org/10.2217/epi-2017-0076)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Future Science at <https://doi.org/10.2217/epi-2017-0076> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

**Using induced pluripotent stem cells to explore genetic and epigenetic variation
associated with Alzheimer's disease**

Jennifer Imm¹, Talitha L. Kerrigan¹, Aaron Jeffries¹, and Katie Lunnon¹

¹ University of Exeter Medical School, Exeter University, Exeter, UK

* Corresponding author: Katie Lunnon, University of Exeter Medical School, RILD Building
Level 4, Royal Devon and Exeter Hospital, Barrack Rd, Exeter. EX2 5DW. UK. E-mail:
k.lunnon@exeter.ac.uk

ABSTRACT

It is thought that both genetic and epigenetic variation play a role in Alzheimer's disease initiation and progression. With the advent of somatic cell reprogramming into induced pluripotent stem cells it is now possible to generate patient derived cells that are able to more accurately model and recapitulate disease. Furthermore, by combining this with recent advances in (epi)genome editing technologies it is possible to begin to examine the functional consequence of previously nominated genetic variants and infer epigenetic causality from recently identified epigenetic variants. In this review we explore the role of genetic and epigenetic variation in Alzheimer's disease and how the functional relevance of nominated loci can be investigated using induced pluripotent stem cells and (epi)genome editing techniques.

MAIN BODY OF ARTICLE

Alzheimer's disease

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and accounts for approximately 60-80% of all dementia cases worldwide [1]. Dementia is estimated to affect 46.8 million people worldwide, with this set to double every 20 years reaching 131.5 million in 2050 [2]. The disease is characterized by the accumulation of amyloid beta ($A\beta$) plaques, intracellular neurofibrillary tangles of hyperphosphorylated tau [3] and loss of synaptic connections [4]; taken together these lead to neuronal cell death. This is accompanied by cognitive and behavioral changes, such as memory impairments, language disturbance and hallucinations. The early cognitive decline in AD can be attributed to the degeneration of cholinergic neuronal cells found in the cortical and limbic brain regions such as the hippocampus [5] and the basal forebrain [6].

The deposition of senile plaques and tangles does not occur at random, but follows a distinct and characteristic pattern [7-10], starting in the neocortex and then the hippocampus [11], whilst other regions, such as the cerebellum, remain relatively unaffected [12]. This specific topographical distribution correlates with, and explains, the characteristic symptoms of AD; the hippocampus and neocortex are well known for being involved in controlling emotions, memory and higher brain function [13, 14]. The cerebellum on the other hand is responsible for the coordination, motor and voluntary movements, and there are far fewer aberrations in these in AD patients when compared with the prevalence of other symptoms [15]. There is already considerable pathology before the disease is diagnosed [16], with the onset of symptoms sometimes occurring at least 10 years after $A\beta$ is first deposited [17]. This apparent delay in the appearance of symptoms is caused by there being a threshold of cholinergic loss before the brain can no longer compensate and ameliorate the deficit [11]. Although much progress has been made in understanding the cellular pathology of AD, the

treatments currently available only temporarily alleviate some symptoms and do not modify the underlying pathology.

Genetic variation associated with AD

Given the high heritability estimates (~60-80%) for AD based on quantitative genetic studies [18], initial etiological studies have focussed on identifying a genetic basis for disease. Although some AD cases are caused by autosomal dominant mutations in three genes (*APP*, *PSEN1*, *PSEN2*), these account for less than 5% of AD prevalence and are early-onset, occurring before the age of 65 years. Most AD cases are late-onset (>65 years) and sporadic, with no defined etiology. However in recent years, large cohort collections and the relatively inexpensive cost of assessing genetic variation through genome-wide association studies (GWAS) has allowed the identification of common variants associated with risk of developing AD. These studies have demonstrated that late onset Alzheimer's disease (LOAD) is thought to be multifactorial with many different genes and single nucleotide polymorphisms (SNPs) being implicated in, and contributing to, disease onset and progression [18]. The most robustly associated gene with LOAD is Apolipoprotein E (*APOE*), which encodes a polymorphic glycoprotein that is involved in the transport of cholesterol and other lipids [19] alongside neuronal growth [20] and tissue repair [21]. There are three isoforms of *APOE* that all correspond to allelic variation at a single locus, $\epsilon 2$, $\epsilon 3$ and $\epsilon 4$, which can be distinguished by cysteine to arginine substitutions at the amino acid positions 112 and 158 [22]. The $\epsilon 4$ variant confers increased risk of developing LOAD, with each additional copy of the risk allele lowering the mean age of onset [23]. Whilst *APOE* $\epsilon 4$ accounts for approximately 20% of genetic risk for developing LOAD it cannot explain all of disease incidence, as not everyone who is homozygous for $\epsilon 4$ actually develops AD [24]. Aside from *APOE* there are numerous other risk loci (SNPs) that have been implicated in AD. The most recent meta-analysis of nearly 75,000 individuals nominated 19 common genetic variants, of which 11 were novel disease loci [25] (**Table 1**). Interestingly, many of the GWAS loci that have been nominated for AD can be linked to amyloid processing or

inflammation. Whilst risk variants that have been identified from GWAS only confer a relatively modest effect size, with odds ratios (ORs) between 0.73 and 1.22 per loci investigated [26], it is thought that these could act cumulatively to cause the onset of degeneration. Scientists have generated polygenic risk scores (PRS) for AD, which combine the effects of many disease-associated SNPs to predict disease risk [27] and recently it has been reported that the PRS prediction captures nearly all common genetic risk for AD [28]. However, another study has demonstrated that collectively common SNPs for AD only account for a third of phenotypic variance in AD [29]. Recent efforts to explain the missing heritability of AD have used sequencing approaches to identify rare variants, with a larger effect size, with SNPs in *PLD3*, *TREM2*, *TM2D3* and *PICALM* being nominated in recent years [30-34].

Table 1: Summary table of SNPs associated with AD, which reach genome wide significance in Lambert et al, 2013 [25]. Abbreviations: Chr. = Chromosome

SNP	Chr:Position	Closest Gene	Odds Ratio
rs6656401	1:207692049	CR1	1.18
rs6733839	2:127892810	BIN1	1.22
rs10948363	6:47487762	CD2AP	1.10
rs11771145	7:143110762	EPHA1	0.90
rs9331896	8:27467686	CLU	0.86
rs983392	11:59923508	MS4A6A	0.90
rs10792832	11:85867875	PICALM	0.87
rs4147929	19:1063443	ABCA7	1.15
rs3865444	19:51727962	CD33	0.94
rs9271192	6:32578530	HLA-DRB5– HLA-DRB1	1.11
rs28834970	8:27195121	PTK2B	1.10
rs11218343	11:121435587	SORL1	0.77
rs10498633	14:92926952	SLC24A4 RIN3	0.91
rs8093731	18:29088958	DSG2	0.73
rs35349669	2:234068476	INPP5D	1.08
rs190982	5:88223420	MEF2C	0.93
rs2718058	7:37841534	NME8	0.93
rs1476679	7:100004446	ZCWPW1	0.91
rs10838725	11:47557871	CELF1	1.08
rs17125944	14:53400629	FERMT2	1.14
rs7274581	20:55018260	CASS4	0.88

Despite the fact that GWAS and sequencing efforts have been successful in identifying novel genes involved in AD, the majority of SNPs lie outside of coding regions of the genome. These variants are thus unlikely to have direct structural or functional effects on their gene's protein product, and are more likely to affect gene regulation at other loci. By integrating genetic variation with transcriptomic measurements in the same samples, for example from microarray or RNA sequencing experiments, it is possible to correlate disease associated genetic variants with changes in gene expression to identify expression quantitative trait loci (eQTLs). Such disease-associated eQTLs can occur both within the same gene (in *cis*) or distally within another gene (in *trans*). Recent research indicates that SNPs may change expression by initially altering the binding ability of one 'pioneering' transcription factor (TF), which then recruits other TFs. This was shown to occur at a CTCF motif, which if disrupted affects the binding of five different TFs [35]. However, if there are two or more variants in perfect linkage disequilibrium (LD) with one another, the non-random association of loci at different genomic locations, then it is not possible to distinguish which variant is acting as the eQTL. To further complicate matters, many eQTLs act in a cell type specific manner [36]. This is particularly relevant when studying heterogeneous tissues such as the brain or blood or in a disease such as AD, when cellular abundance is known to be altered [37, 38]. In the context of AD, one recent study demonstrated an enrichment for monocyte-specific eQTLs at disease-associated loci, suggesting a role of the innate immune system in AD pathology [39]. In support of this, Karch *et al*, tested whether GWAS LOAD SNPs act as cis-eQTLs for LOAD GWAS genes [40]. They were able to show the AD SNP rs1476679 in *ZCWPW1*, was significantly associated with the expression of *PILRB* and *GATS* in most brain regions, including the hippocampus. Interestingly, *PILRB* acts as a binding partner for *TYROBP*, both of which can be found on microglia [41]. The expression of *TYROBP* is restricted to cells of the immune system such as microglia, and has been shown to be up-regulated in the brains of patients with LOAD. In a recent gene-regulatory network analysis *TYROBP* was shown to be a key causal regulator of a microglial/immune module highlighted as the module most associated with pathophysiology of LOAD. This microglia/immune module was also shown to


contain a number of AD GWAS risk loci, such as *CD33*, *MS4A4A* and *MS4A6A* [39]. Furthermore, *TREM2*, which has been recently nominated from sequencing studies, is known to interact and signal through *TYROBP* [39]. Taken together many network level analyses have highlighted a role for microglia and neuroinflammation in AD risk [39, 40, 42, 43].

A role for epigenomic dysfunction in AD?

Recently, increased understanding about the functional complexity of the genome has led to growing recognition about the likely role of non-sequence-based “epigenetic” variation in AD [44]. Epigenetic processes mediate the reversible regulation of gene expression, occurring independently of DNA sequence, acting principally through chemical modifications to DNA and nucleosomal histone proteins (**Figure 1**). The most widely studied epigenetic modification in human studies is that of DNA methylation, given it is the most stable and longest lasting change.

In general, *in vitro* studies have suggested that there is a trend towards global DNA hypomethylation in AD. For example, one study demonstrated global hypomethylation in a glioblastoma cell line with the *APP*^{SWE} mutation, which occurs in familial AD [45]. Likewise, it was shown that there are lower DNA methylation levels in brain microvascular endothelial cells that were exposed to high levels of synthetic A β ₁₋₄₀ [46]. However, in contrast to this a more recent study using neuroblastoma cells exposed to synthetic A β ₁₋₄₀ showed no significant change in DNA methylation levels [47]. In the context of human post-mortem brain samples there are also some conflicting results; contrasting studies have shown decreased levels of global DNA methylation in AD-associated brain regions such as the entorhinal cortex [48] and hippocampus [49], whilst others report no change [50, 51] or even increased levels in the frontal cortex [52] and hippocampus [53].

Figure 1. Diagram to illustrate the different epigenetic mechanisms that have been identified. (A) Regulation of chromatic structure through post-translational modifications to histone proteins. This can include: acetylation, methylation, SUMOylation, ubiquitylation, citrullination and ADP-ribosylation. (B) Addition of chemical tags to DNA to the 5' end of a cytosine nucleotide. This creates 5-methylcytosine (5mC – the most commonly studied epigenetic mark), 5-hydroxymethylcytosine (5hmC), 5-carboxylcytosine (5caC) and 5-formylcytosine (5fC). (C) Small RNA molecules, such as microRNA can also affect gene expression either through degrading mRNA or altering protein translation.



In recent years, advances in genomic technology have allowed the first genome-scale studies of DNA methylation in AD [54, 55]. To date, all published studies have utilized the Illumina Infinium 450K Methylation Beadarray (450K array) to examine DNA methylation changes at >485,000 loci in post-mortem brain samples. Although these epigenome-wide association studies (EWAS) have been performed on independent sample cohorts, in a range of anatomically distinct cortical brain regions, a number of consistently differentially methylated genes have been identified [56]. Most notably one such gene to be robustly hypermethylated in AD cortex is Ankyrin1 (*ANK1*) [54, 55]. Interestingly, disease-associated *ANK1* hypermethylation has been observed in a tissue-specific manner, with brain regions

affected by AD pathology (entorhinal cortex, superior temporal gyrus and prefrontal cortex) showing significant hypermethylation, whilst the cerebellum, a region largely unaffected by pathology, and pre-mortem blood show no disease-associated changes. The majority of genes identified by EWAS are distinct from those nominated in GWAS with the exception of *BIN1*. However, despite different genes being identified with the two approaches many of these do reside in common pathways [57]. Since the publication of the initial EWAS, there have been additional studies identifying additional differentially methylated genes in AD, including *CRTC1* [58], *APOE* [59] and *TREM2* [60].

To date the majority of AD EWAS have focussed on DNA methylation, with histone modifications considerably less well studied. However, one study has shown that the histone deacetylase (HDAC) inhibitor, sodium butyrate, can improve cognitive function, synaptic density and plasticity in mouse models with inducible overexpression of p25 protein [61]. P25 has been shown to be linked to numerous features of AD such as amyloid and tau pathology alongside memory loss and neurodegeneration [62-64]. These findings have been corroborated by another, who also demonstrated improved memory function after treatment with sodium butyrate in transgenic APPPS1-21 mice [65]. Furthermore, memory improvements were seen even when it was administered at the latest stages of amyloid pathology and were associated with increased expression of genes implicated in associative learning. Other studies have also shown HDACs to have therapeutic utility, such as Depakote [66], phenylbutyric acid [67] and trichostatin A [68]. Whilst these studies are encouraging and show the potential utility of HDACs as therapeutic agents there are, however, a couple of considerations with this approach. First, most models, including the ones we describe, are models of familial AD, which use small numbers of animals and, as such, results should not be over interpreted. Alongside this, these studies use pan-HDAC inhibitors, which are all known to affect multiple HDACs. Whilst it is useful to know that there may be some involvement of histone modifications or HDACs in AD initiation or progression,

these studies do not highlight specifically which ones are implicated. In order to address this, a number of groups have crossed APPPS1-21 mice with those lacking certain HDACs. APPPS1-21 mice that lack HDAC5 show exaggerated memory impairment [69], whilst those lacking HDAC6 have improved memory, but this is achieved without changing amyloid deposition [70]. Another HDAC that could have potential as a therapeutic target is HDAC2, as mice with reduced HDAC2 show increased memory and synaptic plasticity [71]. Therefore, it appears that only specific HDACs show promise as potential drug targets. When using certain HDACs it is important to be aware that they can also affect DNA methylation. For instance it has been shown that Depakote can cause extensive DNA methylation changes including demethylation changes at specific genes such as *MMP2*, *MAGEB2* and *WIF1*, which have been implicated in tumour growth and metastasis [72]. This study supports the concept that various epigenetic marks are in a dynamic relationship with one another and that you cannot necessarily target one without affecting another. Finally, as with any potential drug that is tested on model systems, such as mice, it is important to remember that these rarely translate effectively into humans. One good example of this comes from studies which demonstrated the utility of anti-amyloid antibodies [73]. In these APP-transgenic mice, just one injection of m266, an anti-APP mouse antibody, was able to reverse cognitive deficits without reducing amyloid plaque burden [73]. However, when taken to phase three clinical trials, the human antibody, Solanezumab, did not reduce cognitive decline in those with mild dementia due to AD [74].

Induced pluripotent stem cells: new models for late-onset Alzheimer's disease?

To fully understand and elucidate the mechanisms of disease etiology, extensive modelling must take place. Traditionally, this has been achieved by a number of methods, including both animal (murine) models and primary patient cell lines. Whilst both of these approaches have their own merits, they can prove inconvenient and do not completely and accurately reflect human disease. At present, the AD research field has had a heavy focus on disease modelling through the use of transgenic mouse models [75], as there is a well-developed

understanding of genetic manipulation techniques in this organism. Furthermore, mice are more phylo-genetically related to humans than other simpler model organisms such as *drosophila melanogaster* and *caenorhabditis elegans*, although these do allow for more experimental control than mice. Due to the close relation of mice and humans they also have good utility for studying familial AD, through the use of transgenic mice containing mutations in the *APP* and *PSEN* genes. This has led to advances in our understanding of multiple aspects of AD, in particular amyloid pathology and the differential effects of the various A β peptides. However, despite the extensive use of these transgenic models to study AD, they do not accurately recapitulate AD, as the mice do not display overt neurodegeneration [76-78] or have amyloid plaques [79]. Whilst proven useful for modelling autosomal disease, such as familial AD, the mouse models do not have extensive utility for studying sporadic AD, which has both polygenic and environmental components. Even if it were possible to model the genetics of sporadic AD in transgenic mice the effect sizes of each associated variant would be small and therefore difficult to determine phenotypic outcome. However, there have been murine studies that have targeted replacement of the endogenous murine *Apoe* gene with human *APOE- ϵ 4*. These mice demonstrated reduced spatial learning and a reduction in dendritic spine density in the medial entorhinal cortex [80]. In another study where *APOE* (both ϵ 3/ ϵ 3 and ϵ 4/ ϵ 4) mice were crossed with mice containing a mutant human form of *APP*, the *APOE- ϵ 4xAPP* mice displayed significantly worse spatial memory performance than their *APOE- ϵ 3xAPP* counterparts, but this was also associated with insulin dysfunction [81].

A more promising avenue for modelling SNPs in complex diseases, such as sporadic AD, is through the use of stem cell technology. Embryonic stem cells (ESCs), which are derived from the inner cell mass of an embryo (blastocyst), have the ability to differentiate into any cell in the body [82]. Due to their inherent plasticity, and as genomic variation can be assessed relatively inexpensively through PCR, microarray, or sequencing technology, there is the potential that they could be used to study the effect of disease-associated SNPs on

the functionality of specific cell types. However, whilst useful, the ethical issues implicated with using embryo derived ESCs are numerous. Recent advances in stem cell technology have allowed the production of stem cells derived from adult tissue, such as blood, urine and keratinocytes [83]. These induced pluripotent stem cells (iPSCs) have almost identical characteristics to ESCs: they share the same morphology, can differentiate into any cell type in the body, have unlimited growth and have the same expression pattern of genes [84]; potentially making them a very powerful tool in research.

There are, however, a number of caveats when utilizing iPSCs to model complex diseases that must be considered. Associated with inducing pluripotency are the global cellular epigenetic changes that allow the cells to alter gene expression in order for them to be functionally identical to ESCs. Despite being functionally identical, several groups report that iPSCs have different DNA methylation profiles and gene expression patterns to ESCs [85-88]. Some groups attribute this variation due to an 'epigenetic memory' where iPSCs show residual DNA methylation patterns that are typical of the tissue they originate from [89]. These differentially methylated regions (DMRs) were shown to affect the differentiation potential of the newly formed iPSCs. For example, iPSCs derived from neural and fibroblast progenitors maintained DNA methylation marks at sites associated with haematopoietic lineages, which decreased the potential for these iPSCs to form blood cells. Subsequently, it is possible to reverse these restricting methyl marks by increasing the cells passage number or treatment with chromatin modifying compounds [89]. This treatment is associated with a decrease in DNA methylation at haematopoietic loci and therefore an increase in blood cell fate potential. Therefore, although it would appear that this epigenetic memory can affect the differentiation potential of cells initially, this effect is actually only transient. It has also been observed that certain subsets of cells can become stuck in a partially reprogrammed state. This is due to inefficient DNA demethylation at certain sites or the incomplete repression of TFs [90]. Despite this, these aberrations can be rectified using RNA inhibition of TFs or treatment with DNA methylase inhibitors. Another potential source of epigenetic variation

between ESCs and iPSCs is the microenvironment in which the iPSCs have been generated. Cooper and Newman have demonstrated that there is some correlation between cells' gene expression patterns and the laboratory the cell lines are derived from [91, 92]. This demonstrates that the environment can affect the epigenome and therefore downstream gene expression of cell lines. To fully assess the differences in the epigenomes between iPSCs and ESCs, Lister *et al*, utilized a shotgun bisulphite sequencing technique (MethylC-seq) to look at the whole-genome DNA methylome at single base-pair resolution [93]. This demonstrated that, overall, ESCs and iPSCs are similar, but that there are some inherent differences between their DNA methylomes. The reprogramming of somatic cells generated hundreds of DMRs that could be attributed to both memory from the somatic cell and iPSC specific DNA methylation patterns that are susceptible during the reprogramming process as many DMRs were consistent across independent iPSC lines [86]. All of these studies demonstrate that there are fundamental differences in both the epigenome and gene expression patterns of ESCs and iPSCs. However, there are ways to rectify some of these differences meaning that iPSCs still have utility as disease models, although the differences must be taken into account when interpreting results.

Since the introduction of iPSC technology there have been increasingly more studies utilizing iPSCs for disease modeling and small molecule testing as, theoretically, iPSCs are an exact genetic match of the patient they are derived from. To accurately model AD using iPSCs, the generation of specific neuronal populations are usually necessary, particularly iPSC derived cortical and cholinergic neurons. Generating these requires certain factors, including SB431542 and LDN-193189 [94], which act as inhibitors of TGF- β I and BMP type I receptors respectively. This inhibition prevents SMAD phosphorylation, suppressing cellular renewal and promoting cortical differentiation [95, 96]. A good iPSC model of AD would not only be the correct cell type of interest, but also show the neuropathological features and characteristics of the disease. There have been several studies that have reported that iPSCs show certain disease features [97-100]. More specifically, in AD iPSCs have also

been used to show A β -induced synaptotoxicity [101]. In this study, Nieweg *et al* demonstrated not only that A β altered AMPA receptors post-synaptically and impaired axonal vesicle clustering, but also increased the phosphorylation status of tau, another key characteristic hallmark of AD. Alongside aberrations in tau phosphorylation, degeneration of cortical neurons is also a very prominent clinical feature of AD, and it is believed that this causes the onset of symptoms. Therefore, to truly understand AD as a disease, being able to recapitulate this neuronal cell death is vital. One recent study has shown that iPSC derived basal forebrain cholinergic neurons (BCFNs) heterozygous for *APOE* (ϵ 3/ ϵ 4) are more susceptible to glutamate mediated cell death, whilst also showing an increased A β ₄₂/A β ₄₀ ratio when compared to BCFNs generated from healthy age matched control patients [102].

One of the major utilities for using iPSCs to study AD is the ability to examine the effects of genetic variants with a relatively small effect size on phenotype. One study which takes advantage of this has demonstrated that iPSC-derived neurons carrying genetic variants in *SORL1*, which increase LOAD risk, have reduced response to BDNF treatment. This not only manifests at the level of *SORL1* expression but also impacts APP processing [103]. Furthermore, given that AD has a polygenic component, it is also possible to assess the effect of different combinations of disease-associated SNPs. As it is possible to use iPSCs to generate patient specific neuronal cells, there is the potential to generate libraries of cells with varying combinations of LOAD-associated SNPs and therefore different susceptibilities to disease. Interestingly, two studies have demonstrated this variability in susceptibility using LOAD iPSC-derived neurons [104, 105]. In the first, undertaken by Israel *et al*, they found that neurons from one patient, but not from another, showed AD-associated phenotypes. This included altered levels of secreted A β ₁₋₄₀, higher α GSK3 levels and had significantly increased p-tau/total tau [104]. The second study, conducted by Kondo *et al*, showed differential intracellular A β oligomer accumulation, inducing endoplasmic reticulum and oxidative stress [105]. Taken together these studies show how different genetic backgrounds

can alter disease initiation and progression as well as the complex genetic interplay there is in LOAD. However, being able to investigate the effects of different polygenic risk scores on living and developing neuronal populations will provide more valuable insight into the role genetic variants play in terms of physiological/cellular aberrations and disease progression in LOAD. Importantly, data that is generated through the usage of iPSCs can therefore be compared and contrasted with data collected from molecular studies in human post-mortem tissue to potentially elucidate the disease-specific effects.

Using genetic editing to elucidate the functional consequence of disease-associated variation

Using iPSCs and recent advances in (epi)genetic editing technology it is becoming possible to start teasing apart the underlying mechanisms that may be driving AD pathogenesis. Clustered regularly interspersed short palindromic repeats (CRISPR) uses RNA guided Cas9 nucleases to introduce DNA breaks which can be repaired through homologous recombination, indel mutations or with a vector carrying a desired mutation [106]. CRISPR can be used provided that the sequence of interest is unique compared to the rest of the genome and is upstream of a protospacer adjacent motif (PAM) sequence. The PAM sequence is typically three to five nucleotides long and serves as a binding region for the Cas9 to bind. Unfortunately, this is a requirement of the method and can be technically challenging. Despite the PAM sequences being relatively common throughout the human genome they can often be in the incorrect location relative to the sequence of interest and can make modifying the gene difficult. Furthermore, if the target locus has high homology to another region in the genome then there is the potential for off-target effects resulting in inadvertent mutations [107, 108].

The main advantage of the CRISPR-Cas9 system is that you can create isogenic control lines that only show genetic variation at your disease-specific loci. One recent example of this in the AD field comes from Pires *et al*, who successfully corrected the A79V *PSEN1*

mutation in a patient AD iPSC cell line [109]. These types of control lines are extremely beneficial for studying disease-associated genetic variation, as they enable the minimization of genetic variability as both disease and control lines have the same genetic background. Such isogenic lines have been recently used to study familial AD [105, 110, 111]. One study has shown iPSCs harbouring the *APP*^{SWE} and *PSEN1* M146V mutations have increased total A β production, and up to a threefold increase in the A β ₄₂/A β ₄₀ ratio when compared to their isogenic controls. These changes have been shown to correlate to neuronal identity, maturity and mutation load [112].

Whilst it proves relatively simple to use this technique to study the effects of causative mutations, such as those in familial AD, other genetic variants like SNPs associated with sporadic AD are more problematic to model. This is due to the fact that they may only be relevant to diseases such as AD in specific combinations. As an extension to the CRISPR system, it is possible to alter multiple loci using CRISPR-multiplexing [113]. In this system multiple guide RNAs are assembled into the same vector and transfected into the cells allowing the targeting of multiple loci. This tool will undoubtedly prove incredibly useful for LOAD research as it will allow researchers to modify up to seven loci. By modifying multiple disease-associated SNPs, one could investigate the effects of various combinations on cell physiology, protein expression and aggregation. This approach would work very well for the LOAD risk SNPs *BIN1*, *CLU* and *PICALM*, for example, as these have all been shown to interact with A β /tau [114-117]. Therefore by altering these specific SNPs one could investigate how tau and A β pathology changes over time. Another interesting point is that this methodology would allow one to investigate the interaction between disease-associated SNPs with reported relationships, for example *PICALM* and the *APOE* ϵ 4 allele. In a previous study of familial AD patients, a homozygous *PICALM* genotype (rs3851179) was shown to modulate prefrontal cortex volume and cognitive impairment in carriers of the *APOE* ϵ 4 allele [118]. As both proteins are involved in the same A β clearance pathway [119, 120], it is thought that alterations in the endocytic functions of *PICALM* may synergistically

affect *APOE* $\epsilon 4$. This could mean there is a higher likelihood of A β remaining in the brain and therefore increasing plaque formation.

Establishing Causality

An important step for research is to establish whether disease-associated variation is causing disease. This is simpler to test when examining genetic variation, as we know that the SNP has been present in an individual throughout their life course, prior to disease onset. However, when investigating the functional effects of disease-associated epigenetic variation, the relationship is less clear, and it is difficult to determine whether epigenetic changes are a cause, or a consequence of, the disease process. Whilst previous post-mortem brain studies have provided valuable physiologically relevant information about epigenetic changes occurring at later disease stages it is difficult to establish if those alterations actually initiated disease, therefore making it problematic to infer causality. In any disease it is critical to be certain of what is causing disease, but particularly so in AD. First because this is crucial for the design of effective drug therapies to combat disease, and second, because AD neuropathology generally occurs at least 10 years before symptomatic onset, it is important to understand the root cause(s) to be able to monitor and diagnose the disease in its very earliest stages. iPSCs have real utility for determining whether associations identified in EWAS analyses could represent a secondary effect of disease, or could be driving disease progression. Using a modified version of the CRISPR-Cas9 technology it has become possible to alter DNA methylation at specific loci. By fusing the Cas9 protein with the enzymatic domains of TET1 or DNMT3A it is possible to remove, or add methyl groups to DNA respectively [121]. This method builds on previous work [122, 123] where Tet1 and Dnmt3a were fused to TALE proteins to achieve the same effect. By being able to manipulate the epigenetic landscape of cells, particularly at loci associated with disease it will enable researchers to establish whether disease-associated epigenetic variation is causative. These techniques have already been utilized in diseases such as cancer [124, 125], but to our knowledge have not yet been reported in AD research. The

epigenetic status of genes such as *ANK1* which have robust changes in AD would be an excellent initial target for this new methodology. It has the potential to reveal whether the DNA methylation changes seen are truly causative and precede disease initiation, or whether they are a consequence of progression. Even if it is the latter and it is found that these alterations do not cause disease, but occur in the earliest stages of the disease, they could potentially be used as a biomarker for diagnosis prior to symptomatic onset. Alongside this, such changes also tell us something about the disease process and its progression. Given that recent studies have demonstrated robust epigenetic alterations in AD, iPSCs could become a valuable tool in which these studies could be taken further. However, to undertake epigenetic studies in these cells it will be very important to fully understand the epigenetic landscape of the iPSCs themselves, both throughout differentiation and at maturity.

Current challenges to Progress

Whilst it is possible to create disease relevant cells using iPSCs, as with any model, iPSCs also have their limitations. A large concern when using iPSC-derived neurons to model disease is that the resulting neurons represent an immature and fetal population [126-129]. This is of particular concern when studying diseases of aging, such as LOAD. However, efforts are being made to overcome this particular issue. For example by expressing a mutant form of *LMNA*, which is known to cause premature aging. By expressing progerin in the iPSC-derived dopaminergic neurons it was possible to create phenotypes that were resultant of both the induced aging and genetic susceptibility [130]. The aged Parkinson's disease neurons had marked dendrite neurodegeneration, reduced tyrosine-hydroxylase expression and displayed epigenetic markers of aging that were not present in the control populations. Another study directly reprogrammed fibroblasts into neurons, skipping iPSC pluripotency stages, in an attempt to overcome iPSC immaturity [131]. As this protocol does not induce pluripotency the inducible neurons (iNs) display both age-related epigenetic and transcriptomic signatures showing age-associated decreases in RanBP17, a nuclear

transport receptor. Whilst these neurons would prove useful for studying diseases of aged cells, such as AD, it is difficult to make large amounts of primary material as these cells cannot be propagated, unlike the iPSC cells.

FUTURE PERSPECTIVE

Since the pioneering work by Takahashi and Yamanaka in 2006, the use of iPSCs has been able to significantly advance complex disease research. They have enabled researchers to more accurately recapitulate disease phenotypes in a cell culture system. Whilst iPSCs are far from being used therapeutically, they have proven useful for investigating the molecular and genetic underpinnings of LOAD. Once there have been more extensive investigations into the effects of SNP burden and their molecular targets, iPSCs can be used to test the effectiveness of new therapeutic interventions. Although at present iPSC generation and differentiation are costly and time consuming, differentiation protocols are quickening, and the use of an individual's own iPSCs to select their appropriate treatment would be a first step towards personalized medicine, potentially improving the patient's life.

Whilst it is still unknown whether the global epigenetic changes that occur during iPSC generation affect the end epitype of cells, there is still promise that these cells could be used to study the epigenetics of complex diseases. If epigenetic aberrations do prove to be an issue, then these will have to be taken into account during experimental design and analysis. However, before identified changes can be targeted for therapeutic intervention it will be important to determine whether they are causal; with the recent advances in genetic and epigenetic editing technology this will soon be possible. Finally, while there are many questions that still remain unanswered and many challenges ahead when addressing these, with the correct model and methodologies these will hopefully be overcome.

EXECUTIVE SUMMARY

Alzheimer's disease (AD)

- Most prevalent neurodegenerative disorder causing 60-80% of dementia cases worldwide
- Characterised by extracellular depositions of amyloid beta (A β) protein and intracellular neurofibrillary tangles of paired helical filaments of tau

Genetic variation associated with AD

- Through the use of genome wide association studies (GWAS) a number of single nucleotide polymorphisms (SNPs) have been associated with late onset AD
- Many GWAS loci implicated in disease have been linked to amyloid processing and inflammation

A role for epigenomic dysfunction in AD?

- Recent epigenome wide association studies (EWAS) have identified a number of loci that are differentially methylated in disease
- The majority of genes identified by EWAS are distinct from those nominated in GWAS with the exception of BIN1.

Induced pluripotent stem cells (iPSCs): new models for late-onset AD?

- Through somatic cell reprogramming it is possible to generate induced pluripotent stem cell (iPSC) derived neuronal cells
- These iPSC-derived neuronal cells have been shown to reflect some disease features
- iPSC-derived neuronal cells can be used to assess the effect of polygenic risk on physiological/cellular changes and disease progression

Using genetic editing to elucidate the functional consequence of disease-associated variation

- Clustered regularly interspersed short palindromic repeats (CRISPR) uses RNA guided Cas9 nucleases to introduce modifications in the genome

- CRISPR-multiplexing can be used to edit multiple loci within the genome

Establishing Causality

- iPSC models have utility in determining whether loci identified from GWAS and EWAS are causative in the disease process
- Using CRISPR the epigenetic landscape of cells can be altered to establish whether DNA methylation changes associated with disease are causative

FINANCIAL DISCLOSURES/ ACKNOWLEDGEMENTS

This work was funded by an Alzheimer's Society project grant to KL (grant number AS-PG-2 14-038), an Alzheimer's Research UK network co-operation grant to KL (grant number ARUK-NCG2017A-5) and an Alzheimer's Association new investigator research grant to KL (grant number NIRG-14-320878). JI is supported by the Alzheimer's Society Doctoral Training Centre in Dementia Research at the University of Exeter (grant number AS-DTC-2014-030) and the Garfield Weston Foundation. The authors declare no conflicts of interest.

REFERENCES AND REFERENCE ANNOTATIONS

1. Association AS. What Is Dementia?
2. Prince M, Wimo A, Guerchet M, Ali G, Wu Y, Prina M. The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. *Alzheimer's Disease International* 1-87 (2015).
3. Blurton-Jones M, Laferla FM. Pathways by which Abeta facilitates tau pathology. *Current Alzheimer research* 3(5), 437-448 (2006).

4. Butterfield DA, Boyd-Kimball D. Amyloid beta-peptide(1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. *Brain pathology (Zurich, Switzerland)* 14(4), 426-432 (2004).
5. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. *Acta neuropathologica* 82(4), 239-259 (1991).
6. Rasool CG, Svendsen CN, Selkoe DJ. Neurofibrillary degeneration of cholinergic and noncholinergic neurons of the basal forebrain in Alzheimer's disease. *Annals of neurology* 20(4), 482-488 (1986).
7. Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. *Brain pathology (Zurich, Switzerland)* 1(3), 213-216 (1991).
8. Kalus P, Braak H, Braak E, Bohl J. The presubicular region in Alzheimer's disease: topography of amyloid deposits and neurofibrillary changes. *Brain research* 494(1), 198-203 (1989).
9. Rogers J, Morrison JH. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 5(10), 2801-2808 (1985).
10. Van Hoesen GW, Hyman BT. Hippocampal formation: anatomy and the patterns of pathology in Alzheimer's disease. *Progress in brain research* 83 445-457 (1990).
11. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. *Journal of neurology, neurosurgery, and psychiatry* 66(2), 137-147 (1999).
12. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. *Neurology* 58(12), 1791-1800 (2002).
13. Cragg BG. Autonomic functions of the hippocampus. *Nature* 182(4636), 675-676 (1958).
14. Diamond IT, Hall WC. Evolution of neocortex. *Science (New York, N.Y.)* 164(3877), 251-262 (1969).

15. Morris RG, Garrud P, Rawlins JN, O'keefe J. Place navigation impaired in rats with hippocampal lesions. *Nature* 297(5868), 681-683 (1982).
16. Jack CR, Jr., Knopman DS, Jagust WJ *et al.* Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet neurology* 9(1), 119-128 (2010).
17. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. *Annals of neurology* 45(3), 358-368 (1999).
18. Gatz M, Reynolds CA, Fratiglioni L *et al.* Role of genes and environments for explaining Alzheimer disease. *Archives of general psychiatry* 63(2), 168-174 (2006).
19. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. *Neurobiology of aging* 26(3), 355-361 (2005).
20. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. *Science (New York, N.Y.)* 264(5160), 850-852 (1994).
21. Huang Y. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. *Trends in molecular medicine* 16(6), 287-294 (2010).
22. Zlokovic BV. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. *JAMA neurology* 70(4), 440-444 (2013).
23. Corder EH, Saunders AM, Strittmatter WJ *et al.* Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science (New York, N.Y.)* 261(5123), 921-923 (1993).
24. Slioter AJ, Cruts M, Kalmijn S *et al.* Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. *Archives of neurology* 55(7), 964-968 (1998).
25. Lambert JC, Ibrahim-Verbaas CA, Harold D *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nature genetics* 45(12), 1452-1458 (2013).

- ** Identified 19 loci associated with AD, 11 of which had not previously been implicated, highlighting new pathways that could play a role in AD.
26. Ebbert MT, Ridge PG, Wilson AR *et al.* Population-based analysis of Alzheimer's disease risk alleles implicates genetic interactions. *Biological psychiatry* 75(9), 732-737 (2014).
 27. Escott-Price V, Sims R, Bannister C *et al.* Common polygenic variation enhances risk prediction for Alzheimer's disease. *Brain : a journal of neurology* 138(Pt 12), 3673-3684 (2015).
 28. Escott-Price V, Shoai M, Pither R, Williams J, Hardy J. Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease. *Neurobiology of aging* 49 214.e217-214.e211 (2017).
 29. Ridge PG, Mukherjee S, Crane PK, Kauwe JS, Alzheimer's Disease Genetics C. Alzheimer's disease: analyzing the missing heritability. *PloS one* 8(11), e79771 (2013).
 30. Cruchaga C, Karch CM, Jin SC *et al.* Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. *Nature* 505(7484), 550-554 (2014).
 31. Jakobsdottir J, Van Der Lee SJ. Rare Functional Variant in TM2D3 is Associated with Late-Onset Alzheimer's Disease. 12(10), e1006327 (2016).
 32. Jonsson T, Stefansson H, Steinberg S *et al.* Variant of TREM2 associated with the risk of Alzheimer's disease. *The New England journal of medicine* 368(2), 107-116 (2013).
 33. Guerreiro R, Wojtas A, Bras J *et al.* TREM2 variants in Alzheimer's disease. *The New England journal of medicine* 368(2), 117-127 (2013).
 34. Lord J, Turton J, Medway C *et al.* Next generation sequencing of CLU, PICALM and CR1: pitfalls and potential solutions. *International journal of molecular epidemiology and genetics* 3(4), 262-275 (2012).

35. Tehranchi AK, Myrthil M, Martin T, Hie BL, Golan D, Fraser HB. Pooled ChIP-Seq Links Variation in Transcription Factor Binding to Complex Disease Risk. *Cell* 165(3), 730-741 (2016).
36. Zhernakova DV, Deelen P. Identification of context-dependent expression quantitative trait loci in whole blood. doi:10.1038/ng.3737 (2016).
37. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. *Cold Spring Harbor perspectives in medicine* 1(1), a006189 (2011).
38. Lunnon K, Ibrahim Z, Proitsi P *et al.* Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. *Journal of Alzheimer's disease : JAD* 30(3), 685-710 (2012).
39. Zhang B, Gaiteri C, Bodea LG *et al.* Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. *Cell* 153(3), 707-720 (2013).
- ** Used postmortem brain tissue to construct a gene-regulatory network of LOAD. Demonstrated immune and microglia specific network which contained TYROBP, a binding partner of TREM2, as a key regulator.
40. Karch CM, Ezerskiy LA, Bertelsen S, Goate AM. Alzheimer's Disease Risk Polymorphisms Regulate Gene Expression in the ZCWPW1 and the CELF1 Loci. *PloS one* 11(2), e0148717 (2016).
41. Tato CM, Joyce-Shaikh B, Banerjee A *et al.* The Myeloid Receptor PILR β Mediates the Balance of Inflammatory Responses through Regulation of IL-27 Production. *PloS one* 7(3), (2012).
42. Li X, Long J, He T, Belshaw R, Scott J. Integrated genomic approaches identify major pathways and upstream regulators in late onset Alzheimer's disease. *Scientific reports* 5 12393 (2015).
43. Wes PD, Easton A, Corradi J *et al.* Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer's disease. *PloS one* 9(8), e106050 (2014).

44. Lunnon K, Mill J. Epigenetic studies in Alzheimer's disease: current findings, caveats, and considerations for future studies. *American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics* 162b(8), 789-799 (2013).
45. Sung HY, Choi EN, Ahn Jo S, Oh S, Ahn JH. Amyloid protein-mediated differential DNA methylation status regulates gene expression in Alzheimer's disease model cell line. *Biochemical and biophysical research communications* 414(4), 700-705 (2011).
46. Chen KL, Wang SS, Yang YY, Yuan RY, Chen RM, Hu CJ. The epigenetic effects of amyloid-beta(1-40) on global DNA and neprilysin genes in murine cerebral endothelial cells. *Biochemical and biophysical research communications* 378(1), 57-61 (2009).
47. Taher N, Mckenzie C, Garrett R, Baker M, Fox N, Isaacs GD. Amyloid-beta alters the DNA methylation status of cell-fate genes in an Alzheimer's disease model. *Journal of Alzheimer's disease : JAD* 38(4), 831-844 (2014).
48. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J. Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. *Neurobiology of aging* 31(12), 2025-2037 (2010).
49. Chouliaras L, Mastroeni D, Delvaux E *et al.* Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients. *Neurobiology of aging* 34(9), 2091-2099 (2013).
50. Lashley T, Gami P, Valizadeh N, Li A, Revesz T, Balazs R. Alterations in global DNA methylation and hydroxymethylation are not detected in Alzheimer's disease. *Neuropathology and applied neurobiology* 41(4), 497-506 (2015).
51. Condliffe D, Wong A, Troakes C *et al.* Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain. *Neurobiology of aging* 35(8), 1850-1854 (2014).

52. Coppieters N, Dieriks BV, Lill C, Faull RL, Curtis MA, Dragunow M. Global changes in DNA methylation and hydroxymethylation in Alzheimer's disease human brain. *Neurobiology of aging* 35(6), 1334-1344 (2014).
53. Bradley-Whitman MA, Lovell MA. Epigenetic changes in the progression of Alzheimer's disease. *Mechanisms of ageing and development* 134(10), 486-495 (2013).
54. Lunnon K, Smith R, Hannon E *et al.* Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. *Nature neuroscience* 17(9), 1164-1170 (2014).
- ** One of first EWAS published and robustly implicated epigenetic dysregulation of ANK1 in AD.
55. De Jager PL, Srivastava G, Lunnon K, Burgess J, Schalkwyk LC. Alzheimer's disease: early alterations in brain DNA methylation at ANK1, BIN1, RHBDF2 and other loci. 17(9), 1156-1163 (2014).
- ** One of first EWAS published
56. Lord J, Cruchaga C. The epigenetic landscape of Alzheimer's disease. *Nature neuroscience* 17(9), 1138-1140 (2014).
57. Smith AR, Mill J, Smith RG, Lunnon K. Elucidating novel dysfunctional pathways in Alzheimer's disease by integrating loci identified in genetic and epigenetic studies. *Neuroepigenetics* 6 32-50 (2016).
58. Mendioroz M, Celarain N, Altuna M *et al.* CRTC1 gene is differentially methylated in the human hippocampus in Alzheimer's disease. *Alzheimer's research & therapy* 8(1), 15 (2016).
59. Foraker J, Millard SP, Leong L *et al.* The APOE Gene is Differentially Methylated in Alzheimer's Disease. *Journal of Alzheimer's disease : JAD* 48(3), 745-755 (2015).
60. Smith AR, Smith RG, Condliffe D *et al.* Increased DNA methylation near TREM2 is consistently seen in the superior temporal gyrus in Alzheimer's disease brain. *Neurobiology of aging* 47 35-40 (2016).

61. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. Recovery of learning and memory is associated with chromatin remodelling. *Nature* 447(7141), 178-182 (2007).
62. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. *Neuron* 40(3), 471-483 (2003).
63. Cruz JC, Kim D, Moy LY *et al.* p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 26(41), 10536-10541 (2006).
64. Fischer A, Sananbenesi F, Pang PT, Lu B, Tsai LH. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. *Neuron* 48(5), 825-838 (2005).
65. Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. *Journal of Alzheimer's disease : JAD* 26(1), 187-197 (2011).
66. Kilgore M, Miller CA, Fass DM *et al.* Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology* 35(4), 870-880 (2010).
67. Wiley JC, Pettan-Brewer C, Ladiges WC. Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice. *Aging cell* 10(3), 418-428 (2011).
68. Francis YI, Fa M, Ashraf H *et al.* Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. *Journal of Alzheimer's disease : JAD* 18(1), 131-139 (2009).

69. Agis-Balboa RC, Pavelka Z, Kerimoglu C, Fischer A. Loss of HDAC5 impairs memory function: implications for Alzheimer's disease. *Journal of Alzheimer's disease : JAD* 33(1), 35-44 (2013).
70. Govindarajan N, Rao P, Burkhardt S *et al.* Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. *EMBO molecular medicine* 5(1), 52-63 (2013).
71. Graff J, Rei D, Guan JS *et al.* An epigenetic blockade of cognitive functions in the neurodegenerating brain. *Nature* 483(7388), 222-226 (2012).
72. Milutinovic S, D'alessio AC, Detich N, Szyf M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. *Carcinogenesis* 28(3), 560-571 (2007).
73. Dodart JC, Bales KR, Gannon KS *et al.* Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. *Nature neuroscience* 5(5), 452-457 (2002).
74. Sacks CA, Avorn J, Kesselheim AS. The Failure of Solanezumab - How the FDA Saved Taxpayers Billions. *The New England journal of medicine* 376(18), 1706-1708 (2017).
75. McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. *Trends in genetics : TIG* 22(5), 281-289 (2006).
76. Takeuchi A, Irizarry MC, Duff K *et al.* Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. *The American journal of pathology* 157(1), 331-339 (2000).
77. Irizarry MC, Mcnamara M, Fedorchak K, Hsiao K, Hyman BT. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. *Journal of neuropathology and experimental neurology* 56(9), 965-973 (1997).

78. Irizarry MC, Soriano F, Mcnamara M *et al.* Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 17(18), 7053-7059 (1997).
79. Kitazawa M, Medeiros R, Laferla FM. Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. *Current pharmaceutical design* 18(8), 1131-1147 (2012).
80. Rodriguez GA, Burns MP, Weeber EJ, Rebeck GW. Young APOE4 targeted replacement mice exhibit poor spatial learning and memory, with reduced dendritic spine density in the medial entorhinal cortex. *Learning & memory (Cold Spring Harbor, N.Y.)* 20(5), 256-266 (2013).
81. Chan ES, Shetty MS, Sajikumar S, Chen C, Soong TW, Wong B-S. ApoE4 expression accelerates hippocampus-dependent cognitive deficits by enhancing A β impairment of insulin signaling in an Alzheimer's disease mouse model. *Scientific reports* 6 26119 (2016).
82. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. *Nature* 292(5819), 154-156 (1981).
83. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126(4), 663-676 (2006).
- ** Demonstrated which factors were important for the maintenance and induction of the stem cell phenotype, therefore allowing for the generation of iPSCs.
84. Yamanaka S. A fresh look at iPS cells. *Cell* 137(1), 13-17 (2009).
85. Chin MH, Mason MJ, Xie W *et al.* Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. *Cell stem cell* 5(1), 111-123 (2009).
86. Lister R, Pelizzola M, Kida YS *et al.* Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. *Nature* 471(7336), 68-73 (2011).

87. Mallon BS, Chenoweth JG, Johnson KR *et al.* StemCellDB: the human pluripotent stem cell database at the National Institutes of Health. *Stem cell research* 10(1), 57-66 (2013).
88. Mallon BS, Hamilton RS, Kozhich OA *et al.* Comparison of the molecular profiles of human embryonic and induced pluripotent stem cells of isogenic origin. *Stem cell research* 12(2), 376-386 (2014).
89. Kim K, Doi A, Wen B *et al.* Epigenetic memory in induced pluripotent stem cells. *Nature* 467(7313), 285-290 (2010).
90. Mikkelsen TS, Hanna J, Zhang X *et al.* Dissecting direct reprogramming through integrative genomic analysis. *Nature* 454(7200), 49-55 (2008).
91. Newman AM, Cooper JB. Lab-specific gene expression signatures in pluripotent stem cells. *Cell stem cell* 7(2), 258-262 (2010).
92. Newman AM, Cooper JB. AutoSOME: a clustering method for identifying gene expression modules without prior knowledge of cluster number. *BMC bioinformatics* 11 117 (2010).
93. Lister R, Pelizzola M, Dowen RH *et al.* Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature* 462(7271), 315-322 (2009).
94. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nature biotechnology* 27(3), 275-280 (2009).
95. Lopez-Coviella I, Mellott TM, Kovacheva VP *et al.* Developmental pattern of expression of BMP receptors and Smads and activation of Smad1 and Smad5 by BMP9 in mouse basal forebrain. *Brain research* 1088(1), 49-56 (2006).
96. Shi Y, Kirwan P, Livesey FJ. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. *Nature protocols* 7(10), 1836-1846 (2012).
- ** Found a robust and reproducible way of creating cortical neurons from iPSCs, a method for investigating AD with iPSCs.

97. Moretti A, Bellin M, Welling A *et al.* Patient-specific induced pluripotent stem-cell models for long-QT syndrome. *The New England journal of medicine* 363(15), 1397-1409 (2010).
98. Lee G, Papapetrou EP, Kim H *et al.* Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. *Nature* 461(7262), 402-406 (2009).
99. Carvajal-Vergara X, Sevilla A, D'souza SL *et al.* Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. *Nature* 465(7299), 808-812 (2010).
100. Marchetto MC, Carromeu C, Acab A *et al.* A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. *Cell* 143(4), 527-539 (2010).
101. Nieweg K, Andreyeva A, Van Stegen B, Tanriover G, Gottmann K. Alzheimer's disease-related amyloid-beta induces synaptotoxicity in human iPS cell-derived neurons. *Cell death & disease* 6 e1709 (2015).
102. Duan L, Bhattacharyya BJ, Belmadani A, Pan L, Miller RJ, Kessler JA. Stem cell derived basal forebrain cholinergic neurons from Alzheimer's disease patients are more susceptible to cell death. *Molecular neurodegeneration* 9 3 (2014).
- ** Demonstrates that iPSC-derived neurons are able to recapitulate disease phenotypes and are more susceptible to glutamate mediated cell death.
103. Young Jessica e, Boulanger-Weill J, Williams Daniel a *et al.* Elucidating Molecular Phenotypes Caused by the SORL1 Alzheimer's Disease Genetic Risk Factor Using Human Induced Pluripotent Stem Cells. *Cell stem cell* 16(4), 373-385 (2015).
104. Israel MA, Yuan SH, Bardy C *et al.* Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature* 482(7384), 216-220 (2012).
105. Kondo T, Asai M, Tsukita K *et al.* Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. *Cell stem cell* 12(4), 487-496 (2013).

106. Byrne SM, Mali P, Church GM. Genome editing in human stem cells. *Methods in enzymology* 546 119-138 (2014).
107. Mali P, Yang L, Esvelt KM *et al.* RNA-Guided Human Genome Engineering via Cas9. *Science (New York, N.Y.)* 339(6121), 823-826 (2013).
108. Cong L, Ran FA, Cox D *et al.* Multiplex Genome Engineering Using CRISPR/Cas Systems. *Science (New York, N.Y.)* 339(6121), 819-823 (2013).
109. Pires C, Schmid B, Petraeus C *et al.* Generation of a gene-corrected isogenic control cell line from an Alzheimer's disease patient iPSC line carrying a A79V mutation in PSEN1. *Stem cell research* 17(2), 285-288 (2016).
110. Woodruff G, Young JE, Martinez FJ *et al.* The presenilin-1 DeltaE9 mutation results in reduced gamma-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. *Cell reports* 5(4), 974-985 (2013).
111. Choi SH, Kim YH, Hebisch M *et al.* A three-dimensional human neural cell culture model of Alzheimer's disease. *Nature* 515(7526), 274-278 (2014).
112. Paquet D, Kwart D, Chen A *et al.* Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. *Nature* 533(7601), 125-129 (2016).
113. Cong L, Ran FA, Cox D *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science (New York, N.Y.)* 339(6121), 819-823 (2013).
114. Holler CJ, Davis PR, Beckett TL *et al.* Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer's disease brain and correlates with neurofibrillary tangle pathology. *Journal of Alzheimer's disease : JAD* 42(4), 1221-1227 (2014).
115. Harold D, Abraham R, Hollingworth P *et al.* Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nature genetics* 41(10), 1088-1093 (2009).
116. Xu W, Tan L, Yu JT. The Role of PICALM in Alzheimer's Disease. *Molecular neurobiology* 52(1), 399-413 (2015).
117. Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biological psychiatry* 77(1), 43-51 (2015).

118. Morgen K, Ramirez A, Frolich L *et al.* Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association* 10(5 Suppl), S269-276 (2014).
119. Nordstedt C, Caporaso GL, Thyberg J, Gandy SE, Greengard P. Identification of the Alzheimer beta/A4 amyloid precursor protein in clathrin-coated vesicles purified from PC12 cells. *The Journal of biological chemistry* 268(1), 608-612 (1993).
120. Cirrito JR, Kang JE, Lee J *et al.* Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. *Neuron* 58(1), 42-51 (2008).
121. Liu XS, Wu H, Ji X *et al.* Editing DNA Methylation in the Mammalian Genome. *Cell* 167(1), 233-247 e217 (2016).
122. Bernstein DL, Le Lay JE, Ruano EG, Kaestner KH. TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts. *The Journal of clinical investigation* 125(5), 1998-2006 (2015).
123. Maeder ML, Angstman JF, Richardson ME *et al.* Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. *Nature biotechnology* 31(12), 1137-1142 (2013).
124. Rivenbark AG, Stolzenburg S, Beltran AS *et al.* Epigenetic reprogramming of cancer cells via targeted DNA methylation. *Epigenetics* 7(4), 350-360 (2012).
125. Nunna S, Reinhardt R, Ragozin S, Jeltsch A. Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells. *PloS one* 9(1), e87703 (2014).
126. Weick JP. Functional Properties of Human Stem Cell-Derived Neurons in Health and Disease. *Stem Cells International* 2016 (2016).
127. Stein JL, De La Torre-Ubieta L, Tian Y *et al.* A quantitative framework to evaluate modeling of cortical development by neural stem cells. *Neuron* 83(1), 69-86 (2014).

128. Mariani J, Simonini MV, Palejev D *et al.* Modeling human cortical development in vitro using induced pluripotent stem cells. *Proceedings of the National Academy of Sciences of the United States of America* 109(31), 12770-12775 (2012).
129. Livesey MR, Magnani D, Hardingham GE, Chandran S, Wyllie DJA. Functional properties of in vitro excitatory cortical neurons derived from human pluripotent stem cells. *The Journal of Physiology* 594(22), 6573-6582 (2016).
130. Miller JD. Human iPSC-based Modeling of Late-Onset Disease via Progerin-induced Aging. 13(6), 691-705 (2013).
131. Mertens J, Paquola AC, Ku M *et al.* Directly Reprogrammed Human Neurons Retain Aging-Associated Transcriptomic Signatures and Reveal Age-Related Nucleocytoplasmic Defects. *Cell stem cell* 17(6), 705-718 (2015).
- ** Demonstrate that iPSC-derived neurons do not retain age related signatures, but induced neurons do display age-specific transcriptomic signatures and have age associated decreases in RanBP17.